Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation
Cytomegalovirus (CMV) infection is common following allogeneic hematopoietic stem cell transplant (HSCT) and is a major cause of morbidity and increased mortality. Whilst pharmacotherapy can be effective in the prevention and treatment of CMV, these agents are often expensive, toxic and in some case...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.01694/full |
| _version_ | 1818517743537750016 |
|---|---|
| author | Manar S. Shafat Vedika Mehra Karl S. Peggs Karl S. Peggs Claire Roddie Claire Roddie |
| author_facet | Manar S. Shafat Vedika Mehra Karl S. Peggs Karl S. Peggs Claire Roddie Claire Roddie |
| author_sort | Manar S. Shafat |
| collection | DOAJ |
| description | Cytomegalovirus (CMV) infection is common following allogeneic hematopoietic stem cell transplant (HSCT) and is a major cause of morbidity and increased mortality. Whilst pharmacotherapy can be effective in the prevention and treatment of CMV, these agents are often expensive, toxic and in some cases ineffective due to viral resistance mechanisms. Immunotherapeutic approaches are compelling and early clinical trials of adoptively transferred donor-derived virus-specific T (VST) cells against CMV have demonstrated efficacy. However, significant logistical challenges limit their broad application. Strategies to optimize VST manufacture and cell banking alongside scientific developments to enhance efficacy whilst minimizing toxicity are ongoing. This review will discuss the development of CMV-specific T-cell therapies, the challenges of widespread delivery of VSTs for CMV and explore how VST therapy can change outcomes in CMV infection following HSCT. |
| first_indexed | 2024-12-11T01:00:24Z |
| format | Article |
| id | doaj.art-f9d6a219272a45fcb1f7cae199778889 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-11T01:00:24Z |
| publishDate | 2020-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f9d6a219272a45fcb1f7cae1997788892022-12-22T01:26:20ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-07-011110.3389/fimmu.2020.01694550178Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell TransplantationManar S. Shafat0Vedika Mehra1Karl S. Peggs2Karl S. Peggs3Claire Roddie4Claire Roddie5Research Department of Haematology, UCL Cancer Institute, University College London, Cancer Institute, London, United KingdomResearch Department of Haematology, UCL Cancer Institute, University College London, Cancer Institute, London, United KingdomResearch Department of Haematology, UCL Cancer Institute, University College London, Cancer Institute, London, United KingdomDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, United KingdomResearch Department of Haematology, UCL Cancer Institute, University College London, Cancer Institute, London, United KingdomDepartment of Haematology, University College London Hospitals NHS Foundation Trust, London, United KingdomCytomegalovirus (CMV) infection is common following allogeneic hematopoietic stem cell transplant (HSCT) and is a major cause of morbidity and increased mortality. Whilst pharmacotherapy can be effective in the prevention and treatment of CMV, these agents are often expensive, toxic and in some cases ineffective due to viral resistance mechanisms. Immunotherapeutic approaches are compelling and early clinical trials of adoptively transferred donor-derived virus-specific T (VST) cells against CMV have demonstrated efficacy. However, significant logistical challenges limit their broad application. Strategies to optimize VST manufacture and cell banking alongside scientific developments to enhance efficacy whilst minimizing toxicity are ongoing. This review will discuss the development of CMV-specific T-cell therapies, the challenges of widespread delivery of VSTs for CMV and explore how VST therapy can change outcomes in CMV infection following HSCT.https://www.frontiersin.org/article/10.3389/fimmu.2020.01694/fullcytomegalovirusvirus-specific T cellscellular therapiesantiviral therapyinfection |
| spellingShingle | Manar S. Shafat Vedika Mehra Karl S. Peggs Karl S. Peggs Claire Roddie Claire Roddie Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation Frontiers in Immunology cytomegalovirus virus-specific T cells cellular therapies antiviral therapy infection |
| title | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| title_full | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| title_fullStr | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| title_full_unstemmed | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| title_short | Cellular Therapeutic Approaches to Cytomegalovirus Infection Following Allogeneic Stem Cell Transplantation |
| title_sort | cellular therapeutic approaches to cytomegalovirus infection following allogeneic stem cell transplantation |
| topic | cytomegalovirus virus-specific T cells cellular therapies antiviral therapy infection |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.01694/full |
| work_keys_str_mv | AT manarsshafat cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation AT vedikamehra cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation AT karlspeggs cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation AT karlspeggs cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation AT claireroddie cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation AT claireroddie cellulartherapeuticapproachestocytomegalovirusinfectionfollowingallogeneicstemcelltransplantation |